Uptake and diffusion of pharmaceutical innovations in health systems

Innovation in the Biopharmaceutical Industry

Volumn , Issue , 2007, Pages 85-107

  Atun, Rifat A ^a   Gurol Urganci, Ipek ^a   Sheridan, Desmond ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Diffusion of innovation; Pharmaceuticals; Regulatory environment

Indexed keywords

EID: 73649107971     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9789812770974_0005     Document Type: Chapter

References (137)

1. Adams, AS (2001). The case for a medicare drug coverage benefit: a critical review of the empirical evidence. Annual Review of Public Health, 22, 49-61.
2. Armstrong, EP and PC Langley (1996). Disease management programs. American Journal of Health System Pharmacy, 53(1), 53-58.
3. Atun, RA and I Gurol-Urganci (2006). Factors influencing the uptake and diffusion of pharmaceutical innovations: a systematic review. Imperial College London, Tanaka Business School Discussion Paper.
4. Atun, RA and N Menabde (2007). Health systems and systems thinking. In Health Systems andCommunicableDiseases:Challenges to Transitional Societies, RJCoker, RAAtun and M McKee (eds.). European Observatory in Health Systems and Open University Press, forthcoming.
5. Atun, RA et al. (2005). Analysis of how the health systems context shapes responses to the control of human immunodeficiency virus: case-studies from the Russian Federation. Bulletin of the World Health Organization, 83(10), 730-738.
6. Atun, RA et al. (2007a). Diffusion of complex health innovations-implementation of primary care reforms in Bosnia and Herzegovina: qualitative study. Health Policy and Planning, 22(1), 28-39.
7. Atun, RA et al. (2007b). Innovation, patents and economic growth. International Journal of Innovation Management, 11(2), 279-297.
8. Bae, JP (1997). Drug patent expirations and the speed of generic entry. Health Services Research, 32(1), 87-101.
9. Bateman, DN et al. (1996). A prescribing incentive scheme for non-fundholding general practices: an observational study. British Medical Journal, 313(7056), 535-538.
10. Berndt, E (2005). The U.S. pharmaceutical industry why major growth in times of cost containment. Health Affairs, 20(2), 100-114.
11. Blustein, J (2000). Drug coverage and drug purchases by medicare beneficiaries with hypertension. Health Affairs, 19(2), 219-230.
12. Bradlow, J and A Coulter (1993). Effect of fundholding and indicative prescribing schemes on general practitioners’ prescribing costs. British Medical Journal, 307(6913), 1186-1189.
13. Brouwers, CA, MB Silverstein and T Wolff (2004). Adverse consequences of OECD government interventions in pharmaceutical markets on the U.S. economy and consumer. BCG White Paper.
14. Burstall, ML (1997). The management of the cost and utilisation of pharmaceuticals in the United Kingdom. Health Policy, 41 (Suppl), S27-S43.
15. Calfee, JE (2000). The increasing necessity for market-based pharmaceutical prices. Pharmacoeconomics, 18(Suppl 1), 47-57.
16. Calfee, JE (2001). Pharmaceutical price controls and patient welfare. Annals of Internal Medicine, 134(11), 1060-1064.
17. Carrin, G and P Hanvoravongchai (2003). Provider payments and patient charges as policy tools for cost-containment: how successful are they in high-income countries? Human Resources for Health, 1(1).
18. Chernew, M, AM Fendrick and RA Hirth (1997). Managed care and medical technology: implications for cost growth. Health Affairs, 16(2), 196-206.
19. Cunningham, PJ (2002). Prescription drug access: not just a Medicare problem. Issue Brief - Center for Studying Health System Change, 51, 1-4.
20. Cutler, DM andMMcClellan (2001). Is technological change in medicine worth it? Health Affairs, 20(5), 11-29.
21. Danzon, PM (1999). The Pharmaceutical Industry. The Wharton School - University of Pennsylvania.
22. Danzon, PM and LW Chao (2000). Cross-national price differences for pharmaceuticals: how large, and why? Journal of Health Economics, 19(2), 159-195.
23. Danzon, PM and M Furukuwa (2003). Prices and availability of pharmaceuticals evidence from nine countries. Health Affairs, July-December(Suppl), Web Exclusives: W3-521-36.
24. Danzon, PM and JD Ketcham (2003). Reference pricing of pharmaceuticals for medicare: evidence from Germany, the Netherlands and New Zealand. NBER Working Papers, # 10007.
25. Danzon, PM and MV Pauly (2002). Health insurance and the growth of pharmaceutical expenditures. Journal of Law & Economics, 45, 587-613.
26. Danzon, PM, RY Wang and L Wang (2005). The impact of price regulation on the launch delay of new drugs: evidence from twenty-five major markets in the 1990s. Health Economics, 14, 269-292.
27. Darba, J (2003). Pharmaceutical expenditure in Spain: evolution and cost containment measures during 1998-2001. European Journal of Health Economics, 4(3), 151-157.
28. Davis, M et al. (1999). Prescription drug coverage, utilization, and spending among Medicare beneficiaries. Health Affairs, 18(1), 231-243.
29. Desiraju, R, H Nair and P Chintagunta (2004). Diffusion of new pharmaceutical drugs in developing and developed nations. International Journal of Research in Marketing, 21(4), 341-357.
30. Dickson, Mand H Redwood (1998). Pharmaceutical reference prices: how do they work in practice? Pharmacoeconomics, 14(5), 471-479.
31. DiMasi, J, R Hansen and H Grabowski (2003). The price of innovation new estimates of drug development costs. Journal of Health Economics, 22(2), 151-185.
32. Dor, A (2004). Does cost sharing affect compliance. NBER Working Paper # 10738.
33. Draborg, E et al. (2005). International comparison of the definition and the practical application of health technology assessment. International Journal of Technology Assessment in Health Care, 21(1), 89-95.
34. Dustan, HP et al. (1992). Report of the task force on the availability of cardiovascular drugs to the medically indigent. Circulation, 85(2), 849-860.
35. Earl-Slater, A (1997). Regulating the price of the UK’s drugs: second thoughts after the government’s first report. British Medical Journal, 314(7077), 365-368.
36. Ellison, S et al. (1997). Characteristics of demand for pharmaceutical products an examination of four cephalosporins. Rand Journal of Economics, 28(3), 426-446.
37. Fattore, G and C Jommi (1998). The new pharmaceutical policy in Italy. Health Policy, 46(1), 21-41.
38. Ferlie, E, L Fitzgerald and M Wood (2000). Getting evidence into clinical practice: an organisational behaviour perspective. Journal of Health Services Research and Policy, 5(2), 96-102.
39. Fitzgerald, L, E Ferlie and C Hawkins (2003). Innovation in healthcare: how does credible evidence influence professionals? Health & Social Care in the Community, 11(3), 219-228.
40. Fortess, EE et al. (2001). Utilization of essential medications by vulnerable older people after a drug benefit cap: importance of mental disorders, chronic pain, and practice setting. Journal of American Geriatric Society, 49(6), 793-797.
41. Freemantle, N (1999). Does the UK National Health Service need a fourth hurdle for pharmaceutical reimbursement to encourage the more efficient prescribing of pharmaceuticals? Health Policy, 46(3), 255-265.
42. Ganslandt, M and KE Maskus (2004). Parallel imports and the pricing of pharmaceutical products: evidence from the European Union. Journal of Health Economics, 23(5), 1035-1057.
43. Gerdtham, UG (1996). The impact of user charges on the consumption of drugs: empirical evidence and economic implications. Pharmacoeconomics, 9(6), 478-483.
44. Gianfrancesco, FD, AP Baines and D Richards (1994). Utilization effects of prescription drug benefits in an aging population. Health Care Financing Review, 15(3).
45. Giuliani, G, G Selke and L Garattini (1998). The German experience in reference pricing. Health Policy, 44(1), 73-85.
46. Goodwin, FK (2003). Impact of formularies on clinical innovation. Journal of Clinical Psychiatry, 64(Suppl 17), 11-14.
47. Grabowski, H (1988). Medicaid patients’ access to new drugs. Health Affairs, 7(5), 102-114.
48. Greenhalgh, T, G Robert, P Bate, F Macfarlane and O Kyriakidou (2005). Diffusion of Innovations in Health Service Organisations: A Systematic Literature Review.Oxford: Blackwell.
49. Griffiths, RI et al. (1994).A review of the first year of medicare coverage of erythropoietin. Health Care Financing Review, 15(3), 83-102.
50. Grootendorst, PV et al. (2001). Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs. Canadian Medical Association Journal, 165(8), 1011-1019.
51. Grootendorst, PV et al. (2005). The impact of reference pricing of nonsteroidal antiinflammatory agents on the use and costs of analgesic drugs. Health Services Research, 40(5 Pt 1), 1297-1317.
52. Harris, BL, A Stergachis and LD Ried (1990). The effect of drug co-payments on utilization and cost of pharmaceuticals in a health maintenance organization.Medical Care, 28(10), 907-917.
53. Harris, CM and G Scrivener (1996). Fundholders’ prescribing costs: the first five years. British Medical Journal, 313(7071), 1531-1534.
54. Hazlet, TK and DK Blough. (2002). Health services utilization with reference drug pricing of histamine(2) receptor antagonists in British Columbia elderly.Medical Care, 40(8), 640-649.
55. Hillman, AL et al. (1999). Financial incentives and drug spending in managed care. Health Affairs, 18(2), 189-200.
56. Hivon, M et al. (2005). Use of health technology assessment in decision making: corresponsibility of users and producers? International Journal of Technology Assessment in Health Care, 21(2), 268-275.
57. Hurley, J (1991). The effects of co-payments within drug reimbursement programs. Canadian Public Policy, 17(4), 473-489.
58. Hurley, RE, JE Paul and DA Freund (1989). Going into gatekeeping: an empirical assessment. QRB Quality Review Bulletin, 15(10), 306-314.
59. Huskamp, HA (2003). Managing psychotropic drug costs: will formularies work?s Health Affairs, 22(5), 84-96.
60. Huttin, C (1994). The use of prescription charges. Health Policy, 27(1), 53-73.
61. Huttin, C and J Andral (2000). How the reimbursement system may influence physicians’ decisions results from focus groups interviews in France. Health Policy, 54(2), 67-86.
62. Ioannides-Demos, LL, JE Ibrahim and JJ McNeil (2002).Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes. Pharmacoeconomics, 20(9), 577-591.
63. Jacobzone, S (2005). Pharmaceutical policies in OECD countries: reconciling social and industrial goals. OECD Labour Market and Social Policy Occasional Papers, # 40.
64. Johnson, RE et al. (1997). The impact of increasing patient prescription drug cost sharing on therapeutic classes of drugs received and on the health status of elderlyHMOmembers. Health Services Research, 32(1), 103-122.
65. Kanavos, P and J Costa-Font (2005). Pharmaceutical parallel trade in Europe: stakeholder and competition effects. Economic Policy, 20 (44), 753-798.
66. Kanavos, P and E Mossialos (1999). Outstanding regulatory aspects in the European pharmaceutical market. Pharmacoeconomics, 15(6), 519-533.
67. Kanavos, P and U Reinhardt (2003). Reference pricing for drugs: is it compatible with U.S. health care? Health Affairs, 22(3), 16-30.
68. Kane, NM and RB Saltman (1997). Comparative experience in home care and pharmaceutical policy. Health Policy, 41 (Suppl), S1-S7.
69. Koopmanschap, MAand FF Rutten (2003). The drug budget silo mentality: the Dutch case. Value in Health, 6 (Suppl 1), S46-S51.
70. Kozma, CM, CE Reeder and EW Lingle (1990). Expanding medicaid drug formulary coverage: effects on utilization of related services. Medical Care, 28(10), 963-977.
71. Kyle, M (2006a). Pharmaceutical price controls and entry strategies. Review of Economics and Statistics, in press.
72. Kyle, M(2006b). The role of firm characteristics in pharmaceutical product launches. RAND Journal of Economics, in press.
73. Layers, RJ (1989). Prescription charges, the demand for prescriptions and morbidity. Applied economics, 21(8).
74. Le Pen, C (2003). The drug budget silo mentality: the French case. Value in Health, 6 (Suppl 1), S10-S19.
75. Leibowitz, A, WG Manning and JP Newhouse (1985). The demand for prescription drugs as a function of cost-sharing. Social Science & Medicine, 21(10), 1063-1069.
76. Lexchin, J and P Grootendorst (2004). Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence. International Journal of Health Services, 34(1), 101-122.
77. Lichtenberg, F (2002). Benefits and costs of newer drugs an update. NBERWorking Paper № 8996.
78. Ljungkvist, MO, D Andersson and B Gunnarsson (1997). Cost and utilisation of pharmaceuticals in Swedens. Health Policy, 41(Suppl 1), S55-S69.
79. Lopez-Casasnovas, Gand J Puig-Junoy (2000).Reviewof the literature on reference pricing. Health Policy, 54(2), 87-123.
80. Lundkvist, J (2002). Pricing and reimbursement of drugs in Sweden. European Journal of Health Economics, 3(1), 66-70.
81. Lyles, A and FB Palumbo (1999). The effect of managed care on prescription drug costs and benefits. Pharmacoeconomics, 15(2), 129-140.
82. Mace, S and D Taylor (2003). Adherence to NICE guidance for the use of anticholinesterases. Disease Management & Health Outcomes, 11(2), 129-137.
83. Marshall, JK et al. (2002). Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. Canadian Medical Association Journal, 166(13), 1655-1662.
84. Maxwell, M et al. (1993). General practice fundholding: observations on prescribing patterns and costs using the defined daily dose method. British Medical Journal, 307(6913), 1190-1194.
85. McCombs, JS, P Mulani and PJ Gibson (2004). Open access to innovative drugs: treatment substitutions or treatment expansion? Health Care Financing Review, 25(3), 35-53.
86. McGuire, A and M Litt (2003). UK budgetary systems and new health-care technologiess. Value in Health, 6 (Suppl 1), S64-S73.
87. Mrazek, MF and E Mossialos (2004). Regulating pharmaceutical prices. In Regulating Pharmaceuticals in Europe: striving for Efficiency, Equity; E Mossialos, T Walley and MF Mrazek (eds.). London: the European Observatory on Health Systems and Policies, Brussels, and Open University Press.
88. Murray, MD and FW Deardorff (1998). Does managed care fuel pharmaceutical industry growth? Pharmacoeconomics, 14(4), 341-348.
89. Oliver, A, E Mossialos and R Robinson (2004). Health technology assessment and its influence on health-care priority setting. International Journal of Technology Assessment in Health Care, 20(1), 1-10.
90. Pavcnik, N (2000). Do pharmaceutical prices respond to insurance? NBERWorking Papers # 7865.
91. Pilote, L et al. (2002). The effects of cost-sharing on essential drug prescriptions, utilization of medical care and outcomes after acute myocardial infarction in elderly patients. Canadian Medical Association Journal, 167(3), 246-252.
92. Puig-Junoy, J (2004). Incentives and pharmaceutical reimbursement reforms in Spain. Health Policy, 67(2), 149-165.
93. Puig-Junoy, J (2005).What is required to evaluate the impact of pharmaceutical reference pricing? Applied Health Economics and Health Policy, 4(2), 87-98.
94. Rafferty, T, K Wilson-Davis and H McGavock (1997). How has fundholding in Northern Ireland affected prescribing patterns? A longitudinal study. British Medical Journal, 315(7101), 166-170.
95. Rocchi, F, AAddis andNMartini (2004).Current national initiatives about drug policies and cost control in Europe: the Italy example. Journal of Ambulatory Care Management, 27(2), 127-131.
96. Rogers, EM (2005). Diffusion of Innovations. New York: Free Press.
97. Ross-Degnan, D et al. (1993). Examining product risk in context: market withdrawal of zomepirac as a case study. Journal of American Medical Association, 270(16), 1937-1942.
98. Ruof, J et al. (2002). Diffusion of innovations: treatment of Alzheimer’s disease inGermany. Health Policy, 60(1), 59-66.
99. Ryan, M and S Birch (1991). Charging for health care: evidence on the utilisation of NHS prescribed drugs. Social Science & Medicine, 33(6), 681-687.
100. Schneeweiss, S et al. (2004). Net health plan savings from reference pricing for angiotensinconverting enzyme inhibitors in elderly British Columbia residents. Medical Care, 42(7), 653-660.
101. Schneeweiss, S, M Maclure and SB Soumerai (2002a). Prescription duration after drug copay changes in older people: methodological aspects. Journal of American Geriatric Society, 50(3), 521-525.
102. Schneeweiss, S, O Schoffski and GW Selke (1998).What is Germany’s experience on reference based drug pricing and the etiology of adverse health outcomes or substitution? Health Policy, 44(3), 253-260.
103. Schneeweiss, S et al. (2002b). Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CanadianMedical Association Journal, 166(6), 737-745.
104. Schneeweiss, S et al. (2003). Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clinical Pharmacology and Therapeutics, 74(4), 388-400.
105. Schneeweiss, S et al. (2002c). Outcomes of reference pricing for angiotensin-convertingenzyme inhibitors. New England Journal of Medicine, 346(11), 822-829.
106. Schoenman, JA, WN Evans and CL Schur (1997). Primary care case management for Medicaid recipients: evaluation of the Maryland access to care program. Inquiry, 34(2), 155-170.
107. Schoffski, O and Graf von der Schulenburg JM(1997). Unintended effects of a costcontainment policy: results of a natural experiment in Germany. Social Science & Medicine, 45(10), 1537-1539.
108. Schwermann, T, W Greiner and JM Von der Schulenburg (2003). Using disease management and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany. Value in Health, 6 (Suppl 1), S20-S30.
109. Sclar, DA et al. (1994). Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clinical Therapeutics, 16(4), 715-730.
110. Seddon, ME et al. (2001). Quality of ambulatory care after myocardial infarction among Medicare patients by type of insurance and region. American Journal of Medicine, 111(1), 24-32.
111. Sheldon, TA et al. (2004).What’s the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients’ notes, and interviews. British Medical Journal, 329(7473).
112. Sheridan, D (2006). Development and innovation in cardiovascular medicine. Imperial College London Discussion Paper.
113. Soumerai, SB (1990). Withdrawing payment for nonscientific drug therapy: intended and unexpected effects of a large-scale natural experiment. Journal of American Medical Association, 263(6), 831-839.
114. Soumerai, SB et al. (1987). Payment restrictions for prescription drugs under Medicaid: effects on therapy, cost, and equity. New England Journal of Medicine, 317(9), 550-556.
115. Soumerai, SB et al. (1991). Effects of medicaid drug-payment limits on admission to hospitals and nursing homes. New England Journal of Medicine, 325(15), 1072-1077.
116. Soumerai, SB et al. (1994). Effects of a limit on Medicaid drugreimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. New England Journal of Medicine, 331(10), 650-655.
117. Stewart-Brown, S et al. (1995). The effects of fundholding in general practice on prescribing habits three years after introduction of the scheme. British Medical Journal, 311(7019), 1543-1547.
118. Stuart, B(1998). Ability to pay and the decision to medicate.MedicalCare, 36(2), 202-211.
119. Stuart, B et al. (1991). Patterns of outpatient prescription drug use among Pennsylvania elderly. Health Care Financing Review, 12(3), 61-72.
120. Stuart, B and NE Coulson (1993). Dynamic aspects of prescription drug use in an elderly population. Health Services Research, 28(2), 237-264.
121. Stuart, B and C Zacker (1999).Who bears the burden of Medicaid drug copayment policies? Health Affairs, 18(2), 201-212.
122. Szymanski, S and T Valletti (2005). Parallel trade, price discrimination, investment and price caps. Economic Policy, (44).
123. Tamblyn, R et al. (2001). Adverse events associated with prescription drug cost-sharing among poor and elderly persons. Journal of American Medical Association, 285(4), 421-429.
124. Tidd, J (2000). From Knowledge Management to Strategic Competence: measuring Technological, Market and Organizational Innovation. London: Imperial College Press.
125. Vogel, RJ (2004). Pharmaceutical pricing, price controls, and their effects on pharmaceutical sales and research and development expenditures in the European Union. Clinical Therapeutics, 26(8), 1327-1340.
126. Von der Schulenburg, JM(1994). The German health care system at the crossroads. Health Economics, 3(5), 301-303.
127. Von der Schulenburg, JM(2006). The regulatory environment for pharmaceutical innovation in Europe. Imperial College London Discussion Paper.
128. Walser, BL, D Ross-Degnan and SB Soumerai (1996). Do open formularies increase access to clinically useful drugs? Health Affairs, 15(3), 95-109.
129. Weiner, JP et al. (1991). Impact of managed care on prescription drug use. Health Affairs, 10(1), 140-154.
130. Whynes, DK, T Heron and AJ Avery (1997). Prescribing cost savings by GP fundholders: long-term or short-term? Health Economics, 6(2), 209-211.
131. Wilking, N and B Jonsson (2005). A pan-European comparison regarding patient access to cancer drugs. Karolinska Institute.
132. Wilsdon, T and R Nitsche (2004). Innovations in the pharmaceutical sector. Accessible at URL: http://pharmacos.eudra.org/F2/pharmacos/docs/Doc2004/nov/EU%20Pharma%20Innovatio n_25-11-04.pdf.CharlesRiver AssociatesENTR/03/28.
133. Wilson, RP, IBuchan and TWalley (1995). Alterations in prescribing by general practitioner fundholders: an observational study. British Medical Journal, 311(7016), 1347-1350.
134. Wilson, RP et al. (1996). Influences of practice characteristics on prescribing in fundholding and non-fundholding general practices: an observational study. British Medical Journal, 313(7057), 595-599.
135. Wilson, RP et al. (1997). General practice fundholders’ prescribing savings in one region of the United Kingdom, 1991-1994. Health Policy, 42(1), 29-37.
136. Wilson, RP et al. (1999). Therapeutic substitution and therapeutic conservatism as costcontainment strategies in primary care: a study of fundholders and non-fundholders. British Journal of General Practice, 49(443), 431-435.
137. World Health Organization (1999). The World Health Report 1999.WHO.